Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2008

View Archived Issues

Novel treatment options for obesity described in recent patents

Protein tyrosine phosphatase inhibition shows benefit in murine model of spinal cord injury

Prolonged survival following sorafenib treatment in hepatocellular carcinoma

Dynavax enters into supply and option agreement with Novartis for universal influenza vaccine

Shire launches Vyvanse for treatment of adults with ADHD

Reseachers report data on novel PET radioligand for mGluR5 imaging

Large study with IGIV-C reveals no effects in relapsing-remitting multiple sclerosis

Topigen completes enrollment in phase II clinical study of TPI-ASM-8 in asthma

sNDA submitted to FDA for Risperdal Consta Long-Acting Injection in bipolar disorder

Zelos receives regulatory approval from FDA and EMEA for phase III study of ZT-031

Cornerstone receives FDA approval to initiate phase I/II clinical trial of CPI-613 in cancer

European Commission grants approval to Merck Serono to broaden license for Erbitux

Progen terminates PI-88 phase III trial and provides strategy update

Novel oral BACE inhibitor reduces brain Abeta levels in monkeys

European Commission approves Apidra for treatment of children, adolescents with diabetes

CHMP issues positive opinion for Ceplene in acute myeloid leukemia

Amgen reports positive results from phase III trial of denosumab in osteoporosis

CHMP grants positive opinion to Omrix's Evicel human fibrin sealant for hemostasis

Xoma commences phase IIa XOMA-629 study in patients with impetigo

Novel HIV reverse transcriptase inhibitors named in recent Tibotec patent

New adenosine A2B receptor antagonists from Almirall

Paion doses first healthy volunteers in phase I CNS-7056 trial

Alizyme presents results from European phase III Colal-Pred trial

Biocompatibles to acquire BrachySciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...